US equities |
MU $1,097.39 ▲+3.03% NVDA $230.86 ▲+1.09% SNDK $1,787.69 ▲+2.75% INTC $120.00 ▼-0.19% AAPL $330.32 ▼-0.81% GOOGL $338.24 ▼-1.70% TSLA $354.11 ▼-0.20% AMD $615.73 ▲+0.65%
FinancialContent

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.550 -0.170 (-3.60%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
SciSparc Has Been Granted The Patent in the United States for its Core Technology, Used to Treat Central Nervous System Disorders.
Via AB Newswire
Topics Intellectual Property
Advances for Tourette Syndrome, Alzheimer’s Disease, Pain Management, Autism Spectrum Disorder and Epilepsy from Proprietary Compounds: SciSparc Ltd. (NASDAQ: SPRC)
Via Get News
Advances for Tourette Syndrome, Alzheimer's Disease, Pain Management, Autism Spectrum Disorder and Epilepsy from Proprietary Compounds: SciSparc Ltd. (NASDAQ: SPRC) SPRC Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems
Via Viz Release
Topics Intellectual Property
Pharmaceutical company SciSparc Ltd to make progress in treating nervous system disorders in 2022
Via AB Newswire
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >